BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

22 4 2024 05:45:00 提供 Nasdaq GlobeNewswire

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

07 4 2024 13:00:00 提供 Nasdaq GlobeNewswire

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

20 3 2024 05:15:00 提供 Nasdaq GlobeNewswire

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

20 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

11 3 2024 06:45:00 提供 Nasdaq GlobeNewswire

BioNTech Announces Planned Retirement of Sean Marett

07 3 2024 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

06 3 2024 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 

08 2 2024 04:45:00 提供 Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

31 1 2024 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

22 1 2024 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

09 1 2024 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

21 12 2023 07:00:00 提供 Nasdaq GlobeNewswire

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

18 12 2023 12:15:00 提供 Nasdaq GlobeNewswire

BioNTech to Inaugurate First African Site on December 18, 2023

12 12 2023 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

06 11 2023 05:45:00 提供 Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

26 10 2023 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

23 10 2023 10:30:00 提供 Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

23 10 2023 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

19 10 2023 05:45:00 提供 Nasdaq GlobeNewswire

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

16 10 2023 02:30:00 提供 Nasdaq GlobeNewswire